Format
Sort by
Items per page

Send to

Choose Destination

See also: TP53 tumor protein p53 in the Gene database

tp53 in Homo sapiensRattus norvegicusDanio rerioAll 198 Gene records

Search results

Items: 1 to 20 of 18000

1.

The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer.

Xu JZ, Wang WQ, Zhang WH, Xu HX, Gao HL, Zhang SR, Wu CT, Li S, Li H, Xu J, Yu XJ, Liu L.

J Cancer. 2019 Jul 10;10(17):4123-4131. doi: 10.7150/jca.30883. eCollection 2019.

2.

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.

Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X.

Cancer Manag Res. 2019 Jun 21;11:5665-5675. doi: 10.2147/CMAR.S201513. eCollection 2019.

3.

An enhanced genetic model of colorectal cancer progression history.

Yang L, Wang S, Lee JJ, Lee S, Lee E, Shinbrot E, Wheeler DA, Kucherlapati R, Park PJ.

Genome Biol. 2019 Aug 15;20(1):168. doi: 10.1186/s13059-019-1782-4.

4.

Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.

Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T.

Thorac Cancer. 2019 Aug 15. doi: 10.1111/1759-7714.13154. [Epub ahead of print]

PMID:
31414729
5.

Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J, Du M, Wang S, Bai Y, Zhang T, Chen Z, Ma Z, Wang J, Dong G, Sun M, Yin R, Chen F.

Thorac Cancer. 2019 Aug 14. doi: 10.1111/1759-7714.13163. [Epub ahead of print]

PMID:
31414580
6.

Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma of unknown primary.

Boscolo-Rizzo P, Schroeder L, Sacchetto V, Holzinger D, Da Mosto MC, Tirelli G, Dal Cin E, Mantovani M, Menegaldo A, Del Mistro A, Romeo S, Dei Tos AP, Niero M, Rigo S, Dyckhoff G, Hess J, Alemany L, Quer M, León X, Polesel J, Pawlita M, Bertorelle R.

Head Neck. 2019 Aug 15. doi: 10.1002/hed.25915. [Epub ahead of print]

PMID:
31414564
7.

Human germ cell tumours from a developmental perspective.

Oosterhuis JW, Looijenga LHJ.

Nat Rev Cancer. 2019 Aug 14. doi: 10.1038/s41568-019-0178-9. [Epub ahead of print] Review.

PMID:
31413324
8.

Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study.

Lupini L, Scutiero G, Iannone P, Martinello R, Bassi C, Ravaioli N, Soave I, Bonaccorsi G, Lanza G, Gafà R, Loizzi V, Negrini M, Greco P.

Eur J Cancer Care (Engl). 2019 Aug 14:e13137. doi: 10.1111/ecc.13137. [Epub ahead of print]

PMID:
31412428
9.

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30028-8. doi: 10.1016/j.euo.2019.02.004. [Epub ahead of print]

PMID:
31412004
10.

Genomic characterisation of breast fibroepithelial lesions in an international cohort.

Md Nasir ND, Ng CCY, Rajasegaran V, Wong SF, Liu W, Ng GXP, Lee JY, Guan P, Lim JQ, Thike AA, Koh VCY, Loke BN, Chang KTE, Gudi MA, Lian DWQ, Madhukumar P, Tan BKT, Tan VKM, Wong CY, Yong WS, Ho GH, Ong KW; International Fibroepithelial Consortium, Tan P, Teh BT, Tan PH.

J Pathol. 2019 Aug 8. doi: 10.1002/path.5333. [Epub ahead of print]

PMID:
31411343
11.

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.

Zhao S, Liu XY, Jin X, Ma D, Xiao Y, Shao ZM, Jiang YZ.

Theranostics. 2019 Jul 9;9(17):4935-4945. doi: 10.7150/thno.35730. eCollection 2019.

12.

An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.

Cao J, Chen L, Li H, Chen H, Yao J, Mu S, Liu W, Zhang P, Cheng Y, Liu B, Hu Z, Chen D, Kang H, Hu J, Wang A, Wang W, Yao M, Chrin G, Wang X, Zhao W, Li L, Xu L, Guo W, Jia J, Chen J, Wang K, Li G, Shi W.

Oncologist. 2019 Aug 13. pii: theoncologist.2019-0236. doi: 10.1634/theoncologist.2019-0236. [Epub ahead of print]

PMID:
31409745
13.

DNA methylation signature is prognostic of choroid plexus tumor aggressiveness.

Pienkowska M, Choufani S, Turinsky AL, Guha T, Merino DM, Novokmet A, Brudno M, Weksberg R, Shlien A, Hawkins C, Bouffet E, Tabori U, Gilbertson R, Finlay JL, Jabado N, Thomas C, Sill M, Capper D, Hasselblatt M, Malkin D.

Clin Epigenetics. 2019 Aug 13;11(1):117. doi: 10.1186/s13148-019-0708-z.

14.

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.

Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.

Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.

PMID:
31409076
15.

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.

Wu CH, Hwang MJ.

Cancer Med. 2019 Aug 13. doi: 10.1002/cam4.2492. [Epub ahead of print]

16.

Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

Kim JY, Lee E, Park K, Im SA, Sohn J, Lee KS, Chae YS, Kim JH, Kim TY, Jung KH, Park YH; Breast Cancer Committee of the Korean Cancer Study Group.

Breast Cancer Res Treat. 2019 Aug 12. doi: 10.1007/s10549-019-05400-y. [Epub ahead of print]

PMID:
31407230
17.

Clinicopathological and Molecular Study of Peritoneal Carcinomatosis Associated with Non-Small Cell Lung Carcinoma.

Nassereddine H, Sannier A, Brosseau S, Rodier JM, Khalil A, Msika S, Danel C, Couvelard A, Théou-Anton N, Cazes A.

Pathol Oncol Res. 2019 Aug 12. doi: 10.1007/s12253-019-00713-1. [Epub ahead of print]

PMID:
31407221
18.

The Correlation of KRAS Gene Expression and P53 Immunoexpression in Colorectal Adenocarcinoma.

Rachmawati M, Yulianti H, Hernowo BS, Suryanti S, Wijaya I, Rahadiani N, Heriyanto DS, Irianiwati I.

Open Access Maced J Med Sci. 2019 Jun 30;7(12):1940-1945. doi: 10.3889/oamjms.2019.549. eCollection 2019 Jun 30.

19.

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Skoulidis F, Heymach JV.

Nat Rev Cancer. 2019 Aug 12. doi: 10.1038/s41568-019-0179-8. [Epub ahead of print] Review.

PMID:
31406302
20.

SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.

Gomes S, Bosco B, Loureiro JB, Ramos H, Raimundo L, Soares J, Nazareth N, Barcherini V, Domingues L, Oliveira C, Bisio A, Piazza S, Bauer MR, Brás JP, Almeida MI, Gomes C, Reis F, Fersht AR, Inga A, Santos MMM, Saraiva L.

Cancers (Basel). 2019 Aug 10;11(8). pii: E1151. doi: 10.3390/cancers11081151.

Supplemental Content

Loading ...
Support Center